ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RTSN / insiders
COYA (35) NTHI (33) PLYX (31) GNLX (29) ⌘ Pro Terminal →

Retension Pharmaceuticals Inc. (RTSN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$11.36 -3.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.26

Retension Pharmaceuticals Inc. (RTSN) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $93.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RTSN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RTSN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $11.36 (-3.97% 1D, market cap $93.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RTSN ranks #326 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RTSN compare to COYA and NTHI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RTSN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COYA (Coya Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $93.4M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $92.9M). Among the 5-stock peer group, RTSN leads on earnings multiple (N/A) while COYA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RTSN?
▼

For Retension Pharmaceuticals Inc. (RTSN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #326 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.26 (-0.90%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (4)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$20 Bull$11 Base$8 Bear
📬 FREE RTSN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RTSN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY RTSN SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($2.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$11.63+39.1% Next Q
Q2 (-2Q)
53
Grade C-$16.18-16.4% Next Q
Q3 (-1Q)
51
Grade C-$13.52-16% Next Q
Current
48
Grade D$11.36-5.6% Hist 90D α
Trajectory: C (56) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RTSN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RTSN currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.72) and Max Pain ($11.93) forces dealer call-delta covering toward $19.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RTSN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RTSN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

RTSN Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RTSN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RTSN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RTSN)

  • ✓Walkthrough of RTSN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RTSN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.88%
2026-11-02O $11.75H $13.03L $11.20C $11.36VOL 56.7K
SMA50: $13.24
$19.27$16.66$14.06$11.46$8.85$11.362026-10-092026-10-152026-10-212026-10-272026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RTSN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RTSN Butterfly Map → + Track RTSN →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RTSN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RTSN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RTSN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RTSN)

Health Care Rank #326 of 1016 ⚔️ COYA vs RTSN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RTSN vs. COYA, NTHI, PLYX, GNLX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Retension Pharmaceuticals Inc. (RTSN) ranks #326 by composite RQD confidence (48/100, grade D) and #671 by equity capitalization ($93.2M). Within this direct 5-issuer industry benchmark cohort, RTSN leads on earnings valuation at N/A trailing P/E, while COYA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RTSN ACTIVE
Retension Pharmaceuticals Inc.
D 48/100 — — — -3.97% $93.2M Benchmark Subject
COYA
Coya Therapeutics Inc.
D- 35/100 — — -35.0% -9.30% $93.4M /coya-vs-rtsn →
NTHI
NeOnc Technologies Holdings Inc.
E 33/100 — — -35.0% +4.49% $92.9M /nthi-vs-rtsn →
PLYX
Polaryx Therapeutics Inc.
E 31/100 — — -35.0% -5.91% $92.7M /plyx-vs-rtsn →
GNLX
Genelux Corporation
E 29/100 — — -35.0% -0.95% $95.0M /gnlx-vs-rtsn →

2. RTSN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Retension Pharmaceuticals Inc. (RTSN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $93.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. RTSN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RTSN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $11.36 (-3.97% 1D, market cap $93.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RTSN ranks #326 in composite RQD confidence.

How does RTSN compare to COYA and NTHI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RTSN carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COYA (Coya Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $93.4M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $92.9M). Among the 5-stock peer group, RTSN leads on earnings multiple (N/A) while COYA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RTSN?

For Retension Pharmaceuticals Inc. (RTSN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #326 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RTSN trading relative to its 50-day, 200-day, and 52-week technical levels?

RTSN last traded at $11.36 (-3.97% on volume of 58,853 shares), positioning the stock -10.69% below its 50-day simple moving average ($12.72) and -8.61% below its 200-day simple moving average ($12.43). Across its 52-week range of $9.66 to $18.64, RTSN sits at the 18.9% percentile with a 14-day RSI of 54.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.94 to $12.78).

RTSN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are RTSN insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RTSN leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: RTSN RQD Cockpit RTSN 12M Forecast RTSN Earnings & Move RTSN Dividends & DRIP RTSN Insiders & 13F RTSN Whale Options RTSN Profit Sankey RTSN News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RTSN — Retension Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:18:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RTSN scores 48 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars, the fundamental cash engine scores 12 of 20 (ROIC 0%; FCF yield 0%), indicating the source data reports no measurable return on invested capital or free-cash-flow yield. Whale/13F flow scores 4 of 20 for institutional accumulation and options positioning, the weakest pillar in the set, meaning the rating reads institutional positioning as unsupportive. Insider conviction scores 9 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 10 of 20 with a beta of 1.0 and sector sensitivity. Forensic balance sheet scores 13 of 20, supported by an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the upside case rests almost entirely on balance-sheet resilience and a non-negative Piotroski reading, not on current earnings or cash generation, since the source reports zero margins and zero ROIC. The valuation tradeoff is that the source data supplies no P/E, EV/EBITDA, or EPS, so the price of $11.83 cannot be benchmarked against earnings. The distribution warning embedded in the verdict, combined with the weakest pillar being institutional flow, signals that the rating model treats recent positioning as a headwind. This is an analytical framework, not personalized financial advice.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the most recent headline reports Yahoo Finance UK coverage of RTSN market action, institutional positioning, and fundamental catalysts. Investing.com reports that Retension Pharmaceuticals priced its IPO at $12 per share on Nasdaq. Seeking Alpha reports an upsized IPO priced at $12 per share, with a status flagged as Pending. Moomoo covers stock forecasts and analyst ratings. TradingView reports on average basic shares outstanding. Stock Titan reports that the CEO holds 402,577 common shares alongside options priced from $1.43. All news items carry a YELLOW light and a MARKET WIRE impact label.

Risk watch items include the recent price decline of -9.63% and the IPO-related pricing and upsizing references, which are described in source headlines without further detail. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are reported.

Open Questions

  • What are the reported revenues, operating income, and net income for recent periods, given that the financials section is empty?
  • What is the company's cash and debt position and free-cash-flow trajectory, beyond the 0% FCF yield and 0.5 Debt/Equity figures?
  • What is the IPO structure, lockup terms, and use of proceeds referenced in the pricing headlines?
  • Who holds the shares, and what are the 13F and insider transaction details behind the 4/20 whale-flow and 9/20 insider-conviction pillar scores?
  • What clinical, regulatory, or product pipeline drives the company's valuation, given no pipeline data is provided?

RTSN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Retension Pharmaceuticals Inc. (RTSN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RTSN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RTSN Bull vs. Bear Conversation Board — What's Your Call at $11.36?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RTSN 🐻 50% BEARISH CONVICTION
1. Pick Your Side on RTSN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $12.78 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RTSN (D • RQD 48/100) a Buy at $11.83?

Welcome to the RTSN (Retension Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 48/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.46 (-20.0%)
Spot @ $11.83

Pump the brakes on RTSN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RTSN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Retension Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $15.14 (+28.0%)
Spot @ $11.83

RTSN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RTSN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $11.83 (52-wk range $11.12 - $13.73), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%